FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Amylin news from FiercePharma

News

Icahn boosts stake in Amylin

Guess who's knocking at Amylin Pharmaceuticals' door? None other than activist investor Carl Icahn, who boosted his stake in the company to 10.1 million shares, or 7.3 percent. Known for rattling the... Read more...

Amylin: Byetta outperforms Januvia

You have to give them credit for trying. Following all the bad news about Byetta possibly leading to Read more...

Can good Byetta news counteract the bad?

The Byetta saga continues today: Amylin Pharmaceuticals saw its stock fall Friday after a Citi Investment analyst decreed that the diabetes med causes four times as many cases of pancreatitis as... Read more...

Lilly, Amylin suffer on Byetta deaths

Eli Lilly and Amylin Pharmaceuticals have reported four more deaths of patients taking the diabetes drug Byetta. This is in addition to the two deaths that Read more...

Are investors overreacting to Amylin news?

Bad news from the FDA can hurt pharma companies fast and after earlier news this week that Amylin's diabetes drug Byetta was associated with some serious cases of acute pancreatitis, the company's... Read more...

Does Lilly's Byetta extend life?

Yesterday, we reported a little pooh-poohing of a potential deal between Eli Lilly and Byetta partner... Read more...

Novo drug bests Byetta in ADA study

SPOTLIGHT: Novo drug bests Byetta in ADA studyAmylin Pharmaceuticals' stock is suffering from a Novo Nordisk study that showed its experimental diabetes drug liraglutide outperformed Amylin's... Read more...

Lilly diabetes med linked to pancreatitis

A fast-growing Eli Lilly med may be held back by a new warning linking it to acute pancreatitis. After 30 reports of pancreatitis in patients using the injectable diabetes drug Byetta--five of which... Read more...